Navigation Links
VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent

BEDFORD, Mass., Sept. 2 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Annexin-Vivo 750 imaging agent for measuring and monitoring apoptosis and cell death in vivo. The new Annexin-Vivo 750 agent is based on the well established Annexin labeling standard in in vitro research. It is expected to significantly expand research areas and enhance drug development by enabling real time imaging of apoptosis and cell death biomarkers associated with disease progression and therapeutic response in vivo.

Annexin-Vivo 750 targets membrane-bound phosphatidylserine exposed in the outer leaflet of the plasma membrane during the induction of apoptosis and cell death. The new agent was developed through an R&D collaboration with MosaMedix, a pioneer in the development of advanced Annexin V-based products. "Annexin is a gold standard in research for the detection of exposed phosphatidylserine, a hallmark of apoptotic and dying cells," said Kirtland Poss, VisEn's President and CEO. "VisEn and MosaMedix have worked closely together to develop a robust Annexin-based in vivo fluorescent imaging agent for the assessment of apoptosis and cell death in vivo. We expect this agent to open up truly breakthrough research areas, especially along with complementary in vitro readouts and within VisEn's broader fluorescence in vivo imaging agent portfolio." "We are extremely pleased to be working with VisEn, a clear leader in the field of in vivo fluorescent imaging and the perfect partner in enabling the new in vivo imaging applications using our Annexin V technology platforms," said Peter Moonen, CEO of MosaMedix.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense(R), IntegriSense(TM), AngioSense(TM), OsteoSense(R), MMPSense(TM), Cat-K FAST(TM), and now Annexin-Vivo. VisEn also offers specialized lines of in vivo agent labeling platforms, including its proprietary VivoTag(R) fluorescence labeling dyes for custom agent development and its NanoSpark(R) labeling nanoparticles. They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging. All VisEn agents and labels, including the new Annexin-Vivo 750 and Cat-K FAST(TM) agents, are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT(TM)) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at

About MosaMedix

MosaMedix has been established for the development of in vivo diagnostic and therapeutic products based on the Annexin Technology Platform that has potential applications in various medical fields, such as Oncology, Cardiovascular Medicine and Respiratory Medicine. The principals at MosaMedix have advanced the technology for in vitro utilization which has become a "golden standard" in Apoptosis Research. Based on recent discoveries and inventions the company is now focused on the translation of its proprietary technology into clinically valuable applications.

SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent
2. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
3. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
4. VisEn Medical Raises $7 Million in Series B Financing
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
7. OriGene Launches 5,000 Purified Human Proteins from HEK293 Cells
8. Elsevier Global Medical News Launches H1N1 Channel
9. PharmaTelevision Launches the First Daily News Show for the Life Sciences Industry
10. Surface Mount Solutions Launches New Website
11. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
Post Your Comments:
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
Breaking Biology Technology:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):